Anisa Shaker is a Gastroenterology physician affiliated with University of Southern California. OpenAlex indexes 102 publications with 1,397 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1520 San Pablo St
Suite 1000
Los Angeles, CA 900335310
Telephone
323-442-5100Provider last certified this registry record 13 Nov 2020.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Proton pump inhibitor62.3%Omeprazole100%Part D≥32 patientsH2 blocker11.7%Famotidine100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2012–2023 per NIH RePORTER. The latest:
- The role of human esophageal myofibroblasts in regulating the epithelial response in GERD
University of Southern California
FY2023$350,625R01DK118065 - The role of human esophageal myofibroblasts in regulating the epithelial response in GERD
University of Southern California
FY2022$350,625R01DK118065 - The role of esophageal myofibroblasts in alcohol related esophageal squamous cell carcinoma.
University of Southern California
FY2022$195,938R21AA028891
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 54 EXTERNAL ABDOMINAL COMPRESSION AS AN ADJUVANT TO ELICIT ESOPHAGEAL CONTRACTILE RESERVE
Gastrointestinal Endoscopy
2026 - Physiologic and molecular effects of alcohol in the esophagus: a narrative review
Annals of Esophagus
2025 - A novel co-culture system to validate results of a phase I trial testing new treatment for Barrett’s esophagus.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
David Liebeskind, MD
University of Southern California
Lon Schneider, MD
University of Southern California
Amytis Towfighi, MD
University of Southern California
Norah Terrault, MD
University of Southern California
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”